Use of Non-selective Beta blockers in Decompensated Cirrhosis and ACLF

Abstract Purpose of Review Our understanding beta blockers in liver cirrhosis has transformed over the last 40 years. However, questions remain their safety acute decompensation and on chronic failure. Since these conditions are associated with significant morbidity mortality, a critical appraisal recent literature is imperative to help guide clinicians. Recent Findings The latest BAVENO guidelines now recommend carvedilol all patients clinically portal hypertension prevent decompensation. There data which shows blocker use decompensated but concerns refractory ascites. also short-term mortality benefit demonstrated Summary With evidence, it seems will continue increase. Future studies should aim identify biomarkers that can determine who from therapy.